• Klíčová slova
• Bypassing agents, Emicizumab, Factor IX, Factor VIII, Guidelines, Haemophilia, Immune tolerance, Inhibitors,
• MeSH
• faktor IX MeSH
• faktor VIII MeSH
• hemofilie A * farmakoterapie   MeSH
• lékařství * MeSH
• lidé MeSH
• poruchy pohlavních chromozomů * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• dopisy MeSH
• Názvy látek
• faktor IX MeSH
• faktor VIII MeSH

BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor.

• Klíčová slova
• Bypassing agents, Factor IX, Factor VIII, Guidelines, Haemophilia, Immune tolerance, Inhibitors,
• MeSH
• faktor IX metabolismus   MeSH
• faktor VIII metabolismus   MeSH
• hemofilie A metabolismus   MeSH
• lidé MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Geografické názvy
• Evropa MeSH
• Názvy látek
• faktor IX MeSH
• faktor VIII MeSH